彰显创新价值，护航中国药械“走出去”强劲势头

Core Insights - By 2025, China's overseas licensing of innovative drugs is expected to exceed 150 deals, with a total value reaching $130 billion, compared to $50 billion in 2024, indicating significant international recognition of China's pharmaceutical and medical device innovations [1] - The successful global market entry of Chinese pharmaceutical and medical device companies requires a collaborative effort involving various departments, financial institutions, and service systems to enhance pricing power and accessibility [1][5] Group 1: Market Trends and Developments - China's pharmaceutical exports have shifted from raw materials and intermediates to innovative drugs, high-end formulations, and advanced medical devices, with a total export value of $100.895 billion in the first 11 months of last year [5] - The establishment of cross-border procurement platforms, such as the China-ASEAN procurement platform, has facilitated significant transactions, including over 10 million yuan in deals for companies like Haizheng Pharmaceutical and Qilu Pharmaceutical [6] Group 2: Pricing and Regulatory Framework - The introduction of an overseas price certification system for innovative drugs aims to provide companies with a reliable pricing reference, addressing previous issues of price information asymmetry and enhancing international market competitiveness [7] - The National Medical Insurance Administration is working on a pricing mechanism for newly launched drugs to ensure that prices reflect the high investment and risk associated with innovative products, thereby stabilizing prices during the initial market entry phase [8]